Pretomanid is remaining tested as Section of a mix routine which include moxifloxacin and PZA to the treatment of equally drug-prone and drug-resistant tuberculosis (ClinicalTrials.gov identifier: NCT02193776). Bedaquiline, authorised through the US FDA for treatment of multidrug-resistant tuberculosis in 2012, is likewise currently being investiga